TCL Archive ODAC Recommendation for Pertuzumab Signals FDA’s Resolve In Granting Accelerated Approvals September 20, 2013
TCL Archive ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards? November 8, 2002
TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002